Article

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology

2020-12-22

Abstract excerpt

<h4>BACKGROUND</h4> While several key resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world issues limit access to drugs. There is a need for a pragmatic, evidence-based, context-adapted tool to guide clinical management based on molecular biomarkers. <h4>METHODS</h4> A compendium of approved and experimental therapies with associated biomarkers was buil...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a3f3a2b2-ddee-5e8a-bd4b-dd197095e8c4
DOI: 10.1101/2020.12.18.20248521

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncologyDOI 10.1101/2020.12.18.20248521Read

Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.Semantic proximity Read

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read

Overview of Molecular Diagnostics in Irish Clinical OncologySemantic proximity Read

Overview of Molecular Diagnostics in Irish Clinical OncologySemantic proximity Read

Incorporating tumor genomic profiling and drug screening through circulating tumor cell- derived organoids into clinical practice for the management of Gastrointestinal CancersSemantic proximity Read

Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort.Semantic proximity Read

Integrative omics analyses broaden treatment targets in human cancer.Semantic proximity Read

Real-World Landscape of Genomic Medicine in Breast Cancer Revealed by the C-CAT Database: Reappraisal of Drug Accessibility and Clinical Utility in 6,307 PatientsSemantic proximity Read

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.Semantic proximity Read

Cancer of unknown primary (CUP) through the lens of precision oncology – a single institution perspectiveSemantic proximity Read

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologySemantic proximity Read

The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular ProfileSemantic proximity Read